MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma

Varování

Publikace nespadá pod Ekonomicko-správní fakultu, ale pod Středoevropský technologický institut. Oficiální stránka publikace je na webu muni.cz.
Autoři

KOVÁČOVÁ Júlia POPRACH A. BUCHLER T. CHO W.C. SLABÝ Ondřej

Rok publikování 2018
Druh Článek v odborném periodiku
Časopis / Zdroj Clinical Chemistry and Laboratory medicine
Fakulta / Pracoviště MU

Středoevropský technologický institut

Citace
www https://www.degruyter.com/view/j/cclm.2018.56.issue-9/cclm-2017-0861/cclm-2017-0861.xml
Doi http://dx.doi.org/10.1515/cclm-2017-0861
Klíčová slova miRNAs; prediction; renal cell carcinoma; sunitinib; tyrosine kinase inhibitor
Popis Renal cell carcinoma (RCC) accounts for 2%-3% of all malignant tumours. The first-choice treatment in metastatic RCC (mRCC) patients is tyrosine kinase inhibitors (TKIs). Although TKIs may prolong survival of the treated patients who are not primary resistant, almost all of them will eventually develop secondary resistance to the treatment after a progression-free period. To predict treatment response, thus, we need efficient biomarkers for rational indication of TKIs in mRCC. MicroRNAs (miR-NAs) not only play important roles in the pathogenesis of many cancers, including RCC but also have been shown to serve as promising diagnostic, prognostic and predictive biomarkers in various cancers. However, the potential of miRNAs to predict response to therapy with TKIs in mRCC has not yet gained sufficient attention. Because personalisation of the TKIs indication in mRCC presents an important unmet medical need, we summarise research on this topic and give an overall insight on the current knowledge in this field.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.